KDR and metastatic colorectal cancer: The final monoclonal antibody targeting the VEGF-VEGFR interaction is ramucirumab (Cyramza), a VEGFR2 monoclonal antibody approved for the treatment of metastatic colorectal cancer, non-small-cell lung cancer, and gastroesophageal junction adenocarcinoma [277].